Update regarding Nominated Adviser and Broker

IXICO plc

27 December 2023

 

27 December 2023

IXICO plc

("IXICO" or the "Company")

Update regarding Nominated Adviser and Broker

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that, following the completion of the all-share merger between Cavendish Securities plc (previously named Cenkos Securities plc) and Cavendish Financial plc (previously named finnCap Group plc), and as a consequence of internal reorganisation within the Cavendish Group, the Company has changed its Nominated Adviser and Broker from Cavendish Securities plc to Cavendish Capital Markets Limited.

For further information please contact: IXICO plc [phone] Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) [phone] Giles Balleny / Dan Hodkinson (Corporate Finance) Michael F Johnson / Tamar Cranford Smith (Sales) About IXICO IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis. IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients. More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

 

END